Skip to main content

Table 1 Sperm samples and clinical semen analysis.

From: Sperm DNA methylation epimutation biomarker for paternal offspring autism susceptibility

Study sample

Paternal sperm analysis

Sample

Age (years)

Father age (years) upon collection

Father age (years) at pregnancy

Collection date of sample

Offspring autism case/control

Volume (mL)

Concentration (mill/mL)

Total of spermatozoa (mill)

Progressive spermatozoa (%)

Non-progressive spermatozoa (%)

Immotile (%)

Total motile sperm count (time)

(a) Sperm samples and clinical analysis

 IVI 1

42

42

31

7/27/15

Case

2.2

83

182.6

58

11

31

105.91

 IVI 2

44

45

43

7/28/15

Case

1.5

38

57

42

11

47

23.94

 IVI 3

41

41

38

7/29/15

Case

3

68

204

44

11

45

89.76

 IVI 4

38

38

34

7/29/15

Case

3.4

66

224.4

35

11

54

78.54

 IVI 5

37

37

33

7/30/15

Case

1.4

10

14

50

14

36

7

 IVI 6

39

49

40

8/4/15

Case

2.2

23

50.6

31

26

43

15.69

 IVI 7

41

41

31

8/12/15

Case

6

47

282

69

14

17

194.58

 IVI 8

42

42

32

8/14/15

Case

2.5

91

227.5

60

15

25

136.5

 IVI 9

45

45

35

9/9/15

Case

3.5

87

304.5

50

13

37

152.25

 IVI 10

39

31

9/28/15

Case

3

33.3

99.9

44

9

47

43.96

 IVI 11

45

39

12/21/15

Case

4

120

480

50

12

38

240

 IVI 12

35

37

24

9/5/17

Case

5.4

36.3

196.02

43

3

54

84.29

 IVI 13

46

46

35

3/7/16

Case

4.2

17.6

73.92

60

17

23

44.35

 IVI 14

40

40

36

10/11/16

Control

2.8

141.65

396.62

55

10

35

218.14

 IVI 15

41

41

36

10/11/16

Control

1

34.3

34.3

31

18

51

10.63

 IVI 16

46

46

35

10/17/16

Control

2.2

5.5

12.1

29

3

68

3.51

 IVI 17

44

44

33

10/20/16

Control

4.8

10.5

50.4

42

12

46

21.17

 IVI 18

38

38

31

10/21/16

Control

3.2

1.6

5.12

28

13

59

1.43

 IVI 19

36

36

34

11/3/16

Control

6.8

14

95.2

32

3

65

30.46

 IVI 20

41

41

41

3/22/17

Control

2.2

91.8

201.96

49

14

37

98.96

 IVI 21

42

42

32

5/23/17

Control

1.4

42.1

58.94

37

23

40

21.81

 IVI 22

37

37

29

9/6/17

Control

4.2

54

226.8

52

9

39

117.94

 IVI 23

43

43

36

9/6/17

Control

1.8

13

23.4

23

20

57

5.38

 IVI 24

54

54

27

9/15/17

Control

2.5

52

130

48

7

45

62.4

 IVI 25

38

38

34

9/15/17

Control

5.5

1.7

9.35

11

8

81

1.03

 IVI 26

43

43

33

9/22/17

Control

1.5

96

144

35

17

48

50.4

 Mean ± SD 

41 ± 3

42 ± 4

34 ± 5

Offspring autism case

3 ± 1

55 ± 33

184 ± 128

49 ± 11

13 ± 5

38 ± 12

94 ± 71

 Mean ± SD

42 ± 5

42 ± 5

34 ± 3

Offspring control

3 ± 2

43 ± 44

107 ± 114

36 ± 13

12 ± 6

52 ± 14

49 ± 63

 Statistical

comparison

NS

NS

NS

(Case vs. Control), not significant (NS) > 0.05

NS

NS

NS

p < 0.01

NS

p < 0.01

NS

(b) Blinded test sample set 1 analysis

 BS 1

Identified case

Actual case

 BS 2

Identified control

Actual control

 BS 3

Identified control

Actual control

 BS 4*

Identified control

Actual Case*

 BS 5

Identified case

Actual case

 BS 6

Identified case

Actual case

 BS 7

Identified control

Actual control

 BS 8

Identified control

Actual control

(c) IVI blinded test sample set 2 analysis

 BS 9

Identified case

Actual case

 BS 10

Identified case

Actual case

 BS 11

Identified case

Actual case

 BS 12

Identified case

Actual case

 BS 13

Identified control

Actual control

 BS 14*

Identified control

Actual case*

 BS 15

Identified control

Actual control

 BS 16

Identified control

Actual control

 BS 17

Identified control

Actual control

 BS 18

Identified control

Actual control

  1. (a) The samples were provided by IVI-RMA, Valencia, Spain, that collected and performed the clinical analysis of semen volume, sperm concentration and analysis, motility and formal progression analysis, and motility analysis. The mean ± SD for case and control samples is provided. A Students t test was used to assess any statistical differences between case and control groups. (b) Blinded test sample set #1 analysis. The analysis was performed to identify the case or control samples and then confirmed once completed after analysis unblinded. (c) Blinded test sample set #2 analysis. IVI-RMA provided an additional ten blinded samples, and following analysis (Identified) was unblinded to assess accuracy (Actual). The false-negative identifications are indicated with an (*) on the labels